Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Rating of "Moderate Buy" by Brokerages

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $27.50.

KMTS has been the topic of several research reports. Bank of America assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a "buy" rating and a $30.00 price objective on the stock. Wolfe Research started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective for the company. The Goldman Sachs Group reduced their price objective on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a research note on Wednesday, April 16th. Piper Sandler started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "overweight" rating and a $27.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "overweight" rating and a $28.00 price objective for the company.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock traded down $0.28 during trading hours on Wednesday, hitting $14.91. The company had a trading volume of 310,381 shares, compared to its average volume of 458,089. The business's fifty day moving average is $19.53. Kestra Medical Technologies has a fifty-two week low of $14.02 and a fifty-two week high of $26.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same period in the prior year, the business posted ($1.18) EPS.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $756,000. Woodline Partners LP purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $2,510,000. Yu Fan purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $56,880,000. Zimmer Partners LP purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $374,000. Finally, Millennium Management LLC purchased a new stake in shares of Kestra Medical Technologies during the first quarter worth about $11,036,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.